Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome

Current Pharmaceutical Design

Volumn 11, Issue 12, 2005, Pages 1561-1572

  Shimizu, Wataru ^a   Aiba, Takeshi ^a   Antzelevitch, Charles ^b  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CARRIER PROTEIN; CILOSTAZOL; DENOPAMINE; FLECAINIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; ION CHANNEL; ISOPRENALINE; MEXILETINE; NICORANDIL; PHENOTHIAZINE DERIVATIVE; PILSICAINIDE; PINACIDIL; POTASSIUM CHANNEL STIMULATING AGENT; PROPRANOLOL; PSYCHOTROPIC AGENT; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; VERAPAMIL;

ARTIFICIAL HEART PACEMAKER; BRUGADA SYNDROME; CELL FUNCTION; DEFIBRILLATOR; DRUG EFFICACY; DRUG MECHANISM; ENDOCARDIUM; EPICARDIUM; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART PROTECTION; HEART REPOLARIZATION; HEART RIGHT VENTRICLE; HEART VENTRICLE FIBRILLATION; HUMAN; LONG QT SYNDROME; NONHUMAN; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; TORSADE DES POINTES;

ADRENERGIC BETA-ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; ELECTROCARDIOGRAPHY; GENOTYPE; HUMANS; LONG QT SYNDROME; SODIUM CHANNEL BLOCKERS; SYMPATHETIC NERVOUS SYSTEM; SYNDROME; VENTRICULAR FIBRILLATION;

EID: 18844390428     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764823     Document Type: Review

References (101)

1. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991; 252: 704-706.
2. Donger CD, Denjoy I, Berthet M, Neyroud N, Cmaud C, Bennaceur M, et al. KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation 1997; 96: 2778-2781.
3. Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature 1998; 392: 293-296.
4. Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23: 20-21.
5. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, et al. Mutations in the Cardiac Ryanodine Receptor Gene (hRyR2) Underlie Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2001; 103: 196-200.
6. Laitinen PJ, Brown KM, Piippo K, Swan H, Devaney JM, Brahmbhatt B, et al. Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation 2001; 103: 485-490.
7. Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299:251-254.
8. Veldkamp MW, Wilders R, Baartscheer A, Zegers JG, Bezzina CR, Wilde AA. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res 2003; 92: 976-983.
9. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med 200; 344: 1823-1831.
10. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004; 109: 30-35.
11. Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J 1975; 89: 378-390.
12. Moss AJ, Schwartz PJ, Crampton RS, Locati E, Carleen E. The long QT syndrome: a prospective international study. Circulation 1985; 71: 17-21.
13. Zipes DP. The long QT interval syndrome. A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991; 84: 1414-1419.
14. Roden DM, Lazzara R, Rosen MR, Schwartz PJ, Towbin JA, Vincent GM, et al. Multiple mechanisms in the long-QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996-2012.
15. Shimizu W, Ohe T, Kurita T, Takaki H, Aihara N, Kamakura S, et al. Early Afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 1991; 84: 1915-1923.
16. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000; 101: 616-623.
17. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178-1185.
18. Plaster NM, Tawil R, Tristani-Firouzi M, Canun S, Bendahhou S, Tsunoda A, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001; 105: 511-519.
19. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, DuBell WH, et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-639.
20. Ks potassium channel. Nature 1996, 384: 80-83.
21. Ks cardiac potassium current. Nature 1996, 384: 78-80.
22. Kr potassium channel. Cell 1995, 81: 299-307.
23. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy K W, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97: 175-187.
24. Wang Q, Shen J, Splawski I, Atkinson DL, Li ZZ, Robinson JL, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
25. Schwartz PJ, Stramba-Badiale M, Segantini A, Austoni P, Bosi G, Giorgetti R, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998; 338: 1709-1714.
26. Schwartz PJ, Priori SG, Dumaine R, Napolitano C, Antzelevitch C, Stramba-Badiale M, et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med 2000; 343: 262-267.
27. Ackerman MJ, Siu BL, Stumer WQ, Tester DJ, Valdivia CR, Makielski JC, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 2001; 286: 2264-2269.
28. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, et al. Influence of the genotype on the clinical course of the long-QT syndrome. N Engl J Med 1998; 339: 960-965.
29. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.
30. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003; 348: 1866-1874.
31. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995; 92: 2929-2934.
32. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000; 102: 2849-2855.
33. Takenaka K, Ai T, Shimizu W, Kobori A, Ninomiya T, Otani H, et al. Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long QT syndrome. Circulation 2003; 107: 838-844.
34. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade de pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997; 96: 2038-2047.
35. Shimizu W, Antzeleyitch C. Cellular basis for the electrocardiographic features of the LQT1 form of the long QT syndrome: Effects of 3-adrenergic agonists, antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998; 98: 2314-2322.
36. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long QT syndrome. Circulation 1998; 98: 1928-1936.
37. Antzelevitch C, Yan GX, Shimizu W, Burashnikov A. Electrical heterogeneity, the ECG, and cardiac arrhythmias, in Zipes D P, Jalife J (eds): Cardiac Electrophysiology: From Cell to Bedside, 3rd edition. Philadelphia, Saunders WB. Co., 1999; pp. 222-238.
38. Antzelevitch C, Shimizu W, Yan GX, Sicouri S, Weissenberger J, Nesterenko V, et al. The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999; 10:1124-1152.
39. Shimizu W, Antzelevitch C. Cellular and ionic basis for T wave alternans under long QT conditions. Circulation 1999; 99: 1499-1507.
40. Shimizu W, Antzelevitch C. Cellular basis for long QT, transmural dispersion of repolarization and Torsade de Pointes in the long QT syndrome. J Electrocardiol 1999; 32: 177-184.
41. Shimizu W, Antzelevitch C. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000; 35: 778-786.
42. + channel opener to reduce transmural dispersion of repolarization and prevent Torsade de Pointes in LQT1, LQT2 and LQT3 models of the long-QT syndrome. Circulation 2000; 102: 706-712.
43. Moss AJ, Robinson JL, Gessman L, Gillespie R, Zareba W, Schwartz P J, et al. Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol 1999, 84: 876-879.
44. Wilde AAM, Jongbloed RJE, Doevendans PA, Duren DR, Hauer RNW, van Langen IM, et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQT2) patients from KVLQT1-related patients (LQT1). J Am Coll Cardiol 1999; 33: 327-332.
45. Ackerman MJ, Tester DJ, Porter CJ. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999; 74: 1088-1094.
46. Khositseth A, Tester DJ, Will ML, Bell CM, Ackerman MJ. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004; 1: 60-64.
47. Tanabe Y, Inagaki M, Kurita T, Nagaya N, Taguchi A, Suyama K, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forros of congenital long QT syndrome. J Am Coll Cardiol 2001; 37:911-919.
48. Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002; 23: 975-983.
49. Aekerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a genespecific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77: 413-421.
50. Shimizu W. Effects of sympathetic stimulation on various repolarization indices in the congenital long QT syndrome. Ann Noninvasive Electrocardiol 2002; 4: 332-342.
51. Shimizu W, Tanabe Y, Aiba T, Inagaki M, Kurita T, Suyama K, et al. Differential effects of β-blockade on dispersion of repolarization in absence and presence of sympathetic stimulation between LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2002; 39: 1984-1991.
52. Shimizu W, Noda T, Takaki H, Kurita T, Nagaya N, Satomi K, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long QT syndrome. J Am Coll Cardiol 2003; 41: 633-642.
53. + channel blockade and to increases in heart rate: Implications for gene-specific therapy. Circulation 1995; 92: 3381-3386.
54. Zygmunt AC, Eddlestone GT, Thomas GP, Nesterenko VV, Antzelevitch C. Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol 2001; 281: H689-697.
55. Benhorin J, Taub R, Goldmit M, Kerem B, Kass RS, Windman I, et al. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation 2000; 101: 1698-1706.
56. Priori SG, Napolitano C, Schwartz PJ, Bloise R, Crotti L, Ronehetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000; 102: 945-947.
57. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018-1022.
58. Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 2003; 42:1777-1782.
59. + channel opener in the LQT1 form of congenital long QT syndrome. Circulation 1998; 97: 1581-1588.
60. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995; 26: 1299-1309.
61. Aiba T, Shimizu W, Hidaka I, Uemura K, Sunagawa K. Verapamil suppresses torsade de pointes by reducing transmural dispersion of repolarization and preventing early afterdepolarization in acquired model of long-QT syndrome. Circulation 2002; 106(Suppl): 1-22.
62. Hirao H, Shimizu W, Kurita T, Aihara N, Kamakura S, Shimomura K. Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol 1996; 28: 1269-1277.
63. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992; 20: 1391-1396.
64. 3. A marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998; 97: 457-460.
65. Gussak I, Antzelevitch C, Bjerregaard P, Towbin JA, Chaltman BR. The brugada syndrome: clinical, electrophysiological and genetic aspects. J Am Coll Cardiol 1999; 33: 5-15.
66. Alings M, Wilde A. "Brugada" syndrome: Clinical data and suggested pathophysiological mechanism. Circulation 1999; 99: 666-673.
67. Antzelevitch C, Brugada P, Brugada J, Brugada R, Nademanee K, Towbin JA. The Brugada Syndrome. In Camm J (ed): Clinical Approaches to Tachyarrhythmias. Futura Publishing Company, Inc., Armonk, NY 1999; 1-99.
68. Antzelevitch C, Brugada P, Brugada J, Brugada R, Shimizu W, Gussak I, et al Brugada syndrome. A decade of progress. Circ Res 2002; 91: 1114-1118.
69. Priori SG, Napolitano C, Gasparini M, Pappone C, Della Bella P, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105: 1342-1347.
70. Wilde AA, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 2002; 106:2514-2519.
71. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation 2002; 105: 73-78.
72. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 2003; 108: 3092-3096.
73. Nademanee K, Veerakul G, Nimmannit S, Chaowakul V, Bhuripanyo K, Likittanasombat K, et al Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation 1997; 96: 2595-2600.
74. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 1996; 27: 1061-1070.
75. Vatta M, Dumaine R, Varghese G, Richard TA, Shimizu W, Aihara N, et al. Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet 2002; 11: 337-345.
76. Matsuo K, Shimizu W, Kurita T, Inagaki M, Aihara N, Kamakura S. Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 1998; 9: 508-512.
77. Atarashi H, Ogawa S, Harumi K, Hayakawa H, Sugimoto T, Okada R, et al. Characteristics of patients with right bundle branch block and ST-segment elevation in right precordial leads. Am J Cardiol 1996; 78: 581-583.
78. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988; 62: 116-126.
79. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, et al. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ. Res 1991; 69: 1427-1449.
80. Furukawa T, Myerburg RJ, Furukawa N, Bassett AL, Kimura S. Differences in transient outward currents of feline endocardial and epicardial myocytes. Cite Res 1990; 67: 1287-1291.
81. Fedida D, Giles WR. Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J Physiol (Lond) 1991; 442: 191-209.
82. Wettwer E, Amos GJ, Posival H, Ravens U. Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Cite Res 1994; 75: 473-482.
83. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium: Phase 2 Reentry? Circulation 1993; 87: 562-5729.
84. Yan GX, Antzelevitch C, Cellular basis for the electrocardio-graphic J wave. Circulation 1996; 93: 372-379.
85. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation 1999; 100:1660-1666.
86. Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510-515.
87. Shimizu W, Matsuo K, Takagi M, Tanabe Y, Aiba T, Taguchi A, et al Body surface distribution and response to drugs of ST segment elevation in the Brugada syndrome: Clinical implication of 87-leads body surface potential mapping and its application to 12-leads electrocardiograms. J Cardiovasc Electrophysiol 2000; 11: 396-404.
88. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, et al. Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11: 1320-1329.
89. Morita H, Morita ST, Nagase S, Banba K, Nishii N, Tani Y, et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 2003; 42: 1624-1631.
90. Goldgran-Toledano D, Sideris G, Kevorkian JP. Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med 2002; 346: 1591-1592.
91. Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, et al. Electrophysiologic characteristics and implication of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardio12002; 39: 1799-1805.
92. Belhassen B, Viskin S, Fish R, Glick A, Setbon I, Eldar M. Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 1999; 10: 1301-1312.
93. Hermida JS, Denjoy I, Clerc J, Extramiana F, Jarry G, Milliez P, et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 2004; 43: 1853-1860.
94. Alings M, Dekker L, Sadee A, Wilde A. Quiuidine induced electrocardiographic normalization in two patients with Brugada syndrome. PACE 2001; 24: 1420-1422.
95. Shimizu W, Kamakura S. Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol 2001; 34:173-175.
96. Tsuchiya T, Ashikaga K, Honda T, Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 2002; 13: 698-701.
97. Suzuki H, Torigoe K, Numata O, Yazaki S. Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol 2000; 11: 1277-1280.
98. Antzelevitch C, Brugada P, Brugada J, Brugada R, Towbin JA, Nademanee K. Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol 2003; 41: 1665-1671.
99. Lombardi F, Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Design 2003; 9(21): 1703-13.
100. Perrella MA, Yet SF. Role of heme oxygenase-1 in cardiovascular function. Curr Pharm Design 2003; 9(30): 2479-87.
101. Takano H, Ohtsuka M, Akazawa H, Toko H, Harada M, Hasegawa H, et al. Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction. Curr Pharm Design 2003; 9(14): 1121-7.